REcent trial results from the Dermatology Meeting EADV in Madrid —shows rituximab superior to mycophenolate in Pemphigus Vulgaris; RTX 40% vs MMF 9.5% attained complete remission of pemphigus vulgaris, without steroids for > 16 weeks https://t.co/PU9CbQSHJV
Links:
Phase III PEMPHIX Study Shows Genentech’s Rituxan (rituximab) Superior to Mycop…
https://on.ft.com/2phP07w
Oct-16-2019
